- Home
- ABOS vs CRVO Comparison
ABOS vs CRVO Comparison
Compare ABOS & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABOS
- CRVO
- Stock Information
- Founded
- ABOS 1996
- CRVO 2001
- Country
- ABOS United States
- CRVO United States
- Employees
- ABOS N/A
- CRVO N/A
- Industry
- ABOS Biotechnology: Pharmaceutical Preparations
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- ABOS Health Care
- CRVO Health Care
- Exchange
- ABOS Nasdaq
- CRVO Nasdaq
- Market Cap
- ABOS 99.1M
- CRVO 98.3M
- IPO Year
- ABOS 2021
- CRVO N/A
- Fundamental
- Price
- ABOS $1.56
- CRVO $2.13
- Analyst Decision
- ABOS Strong Buy
- CRVO Buy
- Analyst Count
- ABOS 3
- CRVO 8
- Target Price
- ABOS $9.33
- CRVO $38.75
- AVG Volume (30 Days)
- ABOS 379.4K
- CRVO 476.7K
- Earning Date
- ABOS 11-12-2024
- CRVO 11-12-2024
- Dividend Yield
- ABOS N/A
- CRVO N/A
- EPS Growth
- ABOS N/A
- CRVO N/A
- EPS
- ABOS N/A
- CRVO N/A
- Revenue
- ABOS N/A
- CRVO $10,066,550.00
- Revenue This Year
- ABOS N/A
- CRVO $34.17
- Revenue Next Year
- ABOS N/A
- CRVO N/A
- P/E Ratio
- ABOS N/A
- CRVO N/A
- Revenue Growth
- ABOS N/A
- CRVO 116.29
- 52 Week Low
- ABOS $1.54
- CRVO $1.80
- 52 Week High
- ABOS $5.09
- CRVO $26.38
- Technical
- Relative Strength Index (RSI)
- ABOS 30.29
- CRVO 28.45
- Support Level
- ABOS $1.69
- CRVO $1.99
- Resistance Level
- ABOS $1.88
- CRVO $2.43
- Average True Range (ATR)
- ABOS 0.13
- CRVO 0.17
- MACD
- ABOS -0.00
- CRVO 0.31
- Stochastic Oscillator
- ABOS 4.88
- CRVO 26.92
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.